Navigation Links
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Date:10/15/2007

Three-Year Analysis Demonstrates Robust, Highly Statistically Significant

Treatment Effect of Alemtuzumab Compared to Rebif(R)

CAMBRIDGE, Mass., Oct. 15 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today announced that top-line, three-year data from a completed Phase 2 clinical trial comparing alemtuzumab with Rebif(R) (interferon beta- 1a) for the treatment of multiple sclerosis were presented this weekend at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Prague. The results come from an analysis conducted after 36 months of treatment for 334 patients in the three-year trial.

Results of the primary outcomes from this trial were presented by Alastair Compston, professor of neurology and the head of the Department of Clinical Neurosciences at the University of Cambridge, United Kingdom, during the prestigious Charcot Award lecture at ECTRIMS.

Efficacy Results

Overall efficacy results demonstrate that alemtuzumab provides a significant treatment effect that has been found to last three years among patients in the study. Analysis of the first co-primary endpoint showed that patients taking alemtuzumab experienced at least a 73 percent reduction in the risk for relapse after three years of follow up when compared to patients treated with interferon beta-1a. This difference was highly statistically significant in favor of the alemtuzumab patients with a p-value less than the pre-specified value (p=0.00396) assigned for the three-year analysis.

Analysis of the other co-primary endpoint showed that patients taking alemtuzumab experienced at least a 70 percent reduction in the risk for progression of clinically
'/>"/>

SOURCE Genzyme Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
4. Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
5. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
6. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
7. Cobalis Expects to Report Phase III Top-Line Results in May
8. XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
9. Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntingtons Disease
10. UCB Announces Positive Top-Line Phase III Results for Keppra as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014  4WEB Medical announces the formal launch ... ankle osteotomy implants on the market today at ... meeting in Chicago .  The Osteotomy ... osteotomy needs with 74 size options included in one ... of only 15 to 18 implant sizes, which limited ...
(Date:9/19/2014)... Merck (NYSE: MRK ), known as MSD ... Canada , is teaming with celebrity chef and cookbook author ... , an educational program encouraging Hispanics with type 2 diabetes to ... goal to help reduce the risk of serious health problems. Hispanics ... higher risk for developing type 2 diabetes than non-Hispanic white adults, ...
(Date:9/19/2014)... 2014  Diplomat, the nation,s largest independent specialty pharmacy, ... to the Board of Directors on September 15, 2014. ... serve as chair of the Audit Committee. ... financial, compliance and operating experience in the health care ... chief financial officer, chief operating officer and secretary of ...
Breaking Medicine Technology:4WEB Medical Unveils 3D-Printed Osteotomy Truss System 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5David Dreyer Appointed to Diplomat Board of Directors 2
... AVIV, Israel , June 29, 2010 ... invasive, accurate,diagnosis of heart diseases, announced today that its ... intended for,improved diagnostic performance of Stress ECG, has been ... is an add-on system with the,HyperQ technology which is ...
... ,, NEW YORK , ... the "Company") (NYSE Amex: NBS ), an international ... , announced on June 15, 2010 that ... government,inspection by the State Food and Drug Administration ("SFDA") ...
Cached Medicine Technology:BSP Granted CE Mark for its HyperQ AD-100 Product Enabling Improved Diagnostic Performance of Stress ECG 2NeoStem Pharmaceutical Subsidiary Announces Two cGMP Lines are Now Fully Operational in New Facility 2NeoStem Pharmaceutical Subsidiary Announces Two cGMP Lines are Now Fully Operational in New Facility 3
(Date:9/19/2014)... “Copay coupons,” a drug manufacturer marketing ... among patients with prescription drug coverage, may now be ... report from the Department of Health and Human ... laws prohibit suppliers from offering side-payments to increase sales ... , The report highlights that two recent surveys, including ...
(Date:9/19/2014)... Unbound , an international humanitarian organization based ... the Philippines being affected by both a tropical storm and ... to the nearest public schools while others moved to higher ... winds to portions of the northern Philippines. , The ... with more than 10 feet of water. , “It ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- As kids ... the targets of cyberbullies, according to a recent study. ... grades 5 through 8 found that verbal and physical ... patterns vary, bullying intervention and prevention strategies must address ... bullying among boys and girls, the researchers said. The ...
(Date:9/19/2014)... of human cancers have abnormally upregulated chemical signals ... are controlled during tumor formation is not fully ... Fayngerts, PhD, both researchers in the department of ... of Medicine, University of Pennsylvania, and colleagues report ... cancer by targeting these pathways. , Lipid second ...
(Date:9/19/2014)... (Lebanon, NH 9/18/14) A leading Dartmouth researcher, working with ... co-authored a paper published today in the Journal ... telomeres increase the risk of melanoma. , "For the ... the length of these telomeres play a part in ... the study Mark Iles, PhD, School of Medicine at ...
Breaking Medicine News(10 mins):Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:New cancer drug target involving lipid chemical messengers 2Health News:Melanoma risk found to have genetic determinant 2
... in U.S., Canada, study says , FRIDAY, April 16 ... places across the United States and Canada could save ... die of cardiac arrest each year, researchers report. , ... in more limited setting, such as casinos or airports, ...
... Inserting new valve within the valve might help high-risk ... -- If an artificial heart valve derived from a ... implanting a mechanical valve inside the artificial valve could ... and opened, the new valve opens and functions similarly ...
... brain lesions developed in patients taking Lipitor than placebo, ... Cholesterol-lowering statin drugs may slow the progression of multiple ... 81 patients with early-stage MS randomly selected to take ... a placebo. After 12 months of treatment, 55.3 percent ...
... Cardiovascular disease appears to be a major risk factor ... -- People with atrial fibrillation, a form of abnormal heart ... Alzheimer,s disease, a new study finds. , The presence of ... especially among younger patients in the group studied, meaning under ...
... Mo. For seniors, dancing isn,t just for fun; ... by University of Missouri researchers found that participation in ... adults. Improved functionality among seniors can decrease their risk ... as dance-based therapy have the potential to significantly reduce ...
... ... ... Researchers at Drexel University College of Medicine have discovered that a certain type ... critical for cancer growth and movement. When researchers reduced and normalized the levels of this ...
Cached Medicine News:Health News:Public Defibrillators Save Lives 2Health News:Public Defibrillators Save Lives 3Health News:Cholesterol Drugs May Slow MS 2Health News:Abnormal Heart Rhythm Linked to Alzheimer's 2Health News:Abnormal Heart Rhythm Linked to Alzheimer's 3Health News:Dance therapy improves seniors' gait, balance, researcher finds 2Health News:Scientists Report Key Finding in Breast Cancer Research 2Health News:Scientists Report Key Finding in Breast Cancer Research 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: